Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 9,247 | 18,515 | 2,630 | 4,069 | 13,907 |
| TOTAL | $12,302 | $21,501 | $3,172 | $5,203 | $15,581 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 903 | 1,019 | 1,133 | 969 | 1,071 |
| TOTAL | $2,817 | $2,933 | $3,047 | $2,883 | $2,985 |
| Total Assets | $15,119 | $24,434 | $6,219 | $8,086 | $18,566 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,331 | 7,407 | 5,639 | 4,340 | 3,734 |
| Accrued Expenses | 5,183 | 6,542 | 7,650 | 6,929 | 6,240 |
| Other current liabilities | N/A | N/A | N/A | N/A | 3,000 |
| TOTAL | $12,045 | $14,437 | $13,735 | $11,735 | $13,421 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 161 | 313 | 460 | 178 | 302 |
| TOTAL | $161 | $313 | $460 | $178 | $302 |
| Total Liabilities | $12,206 | $14,750 | $14,195 | $11,913 | $13,723 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 64,333 | 57,755 | 56,268 | 32,062 | 28,348 |
| Common Shares | 5 | 5 | 3 | 3 | 3 |
| Retained earnings | -234,280 | -226,810 | -217,244 | -209,108 | -199,841 |
| TOTAL | $2,913 | $9,684 | $-7,976 | $-3,827 | $4,843 |
| Total Liabilities And Equity | $15,119 | $24,434 | $6,219 | $8,086 | $18,566 |